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PURPOSE. To map choroidal (ChT) and retinal thickness (RT) in
healthy subjects and patients with diabetes with and without
maculopathy using three dimensional 1060-nm optical coher-
ence tomography (3D-1060nm-OCT).
METHODS. Sixty-three eyes from 42 diabetic subjects (41–82
years of age; 11 females) grouped according to a custom
scheme using Early Treatment Diabetic Retinopathy Study def-
initions for pathology within 1 disc-diameter of fovea (without
pathology [NDR], microaneurysms [M1], exudates [M2], clini-
cally significant macular edema [CSME]) and 16 eyes from 16
healthy age matched subjects (38–79 years of age; 11 females)
were imaged by 3D-1060nm-OCT performed over a 36°  36°
field of view. Axial length, 45° fundus photographs, body mass
index, plasma glucose, and blood pressure measurements were
recorded. The ChT at the subfoveal location and ChT maps
between RPE and the choroidal–scleral interface were gener-
ated and statistically analyzed.
RESULTS. RT maps show thinning in the NDR group but an
increase in thickness with increasing maculopathy in the tem-
poral and central regions (unpaired t-test; P  0.05). ChT
mapping of all diabetic patients revealed central and inferior
thinning compared to healthy eyes (unpaired t-test; P 0.001).
Subfoveal ChT (mean  SD) for healthy eyes was 327  74
m, which was significantly thicker than all diabetic groups
(214  55 m for NDR, 208  49 m for M1, 205  54 m for
M2, and 211  76 m for CSME (ANOVA P  0.001; Tukey
P  0.001).
CONCLUSIONS. 3D-1060nm-OCT has shown that the central
choroid is thinner in all type 2 diabetic eyes regardless of
disease stage. The choroidal thinning may exceed the magni-
tude of possible choriocapillaris atrophy. In contrast to the
conventional assessment of pathologic thickness change in
several locations, thickness maps allow investigation of the
choroid over the extent of affected areas. (Invest Ophthalmol
Vis Sci. 2011;52:5311–5316) DOI:10.1167/iovs.10-6875
The principal changes in diabetic eye disease are the break-down of the blood–retinal barrier, retinal vasculature in-
tegrity1 and hemodynamic abnormalities.2 Development of
ischemia in the macula caused by capillary nonperfusion is
correlated with vision loss.3 However, because of the high
metabolic demand of the photoreceptors, the supply of glu-
cose and oxygen to the macular region is largely provided by
the choroid.4 Despite the choroid being an integral part of the
nutrient and oxygen exchange with the retina, structural
changes in the choroid and their potential effects on retina
tissue have not previously been investigated in the living eye.
Histologic evidence has shown that diabetic retinopathy
causes atrophy of the choriocapillaris endothelium,5 but exam-
ination of these structural changes in vivo have been hampered
by the limitations of commercial optical coherence tomogra-
phy (OCT) instruments in imaging the choroid–sclera bound-
ary in patients with thick choroids or obtaining an adequate
field of view because of their operation in the 800-nm wave-
length band.6–8 Recently, OCT at 1060 nm has shown the
ability to visualize the choroid because of less scattering caused
by the RPE,9 thereby allowing human choroid thickness (ChT)
to be measured in healthy subjects.10,11 These studies found
that ChT varies with age11 and axial length,10 and suggests that
it could be a reliable biomarker for retinal eye disease.
The aims of this study are to image the choroid in healthy
normal subjects compared to various stages of diabetic eye
disease, mapping its thickness and documenting associated
retinal changes by using retinal thickness (RT) maps.
METHODS
Subjects
Forty-two subjects with type 2 diabetes mellitus and 16 healthy sub-
jects were recruited. Ethical approval was obtained from the School of
Optometry and Vision Sciences, Cardiff University, Ethics Committee,
and the Central and Local Office for Research Ethics Committees. The
studies followed the Declaration of Helsinki, and informed consent
was obtained from all subjects before participation. Exclusion criteria
were systemic diseases other than diabetes, history of retinal surgery,
retinal pathology such as glaucoma and AMD, or physiological varia-
tion from normal. Inclusion criteria were a previous diagnosis of
diabetes type 2. Demographic data of the subject cohort can be found
in Table 1. Retinal status of diabetic eyes was evaluated by an experi-
enced ophthalmologist with slit lamp biomicroscopy with a Volk lens.
All lesions were recorded and eyes were graded according to Early Treatment
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Diabetic Retinopathy Study (ETDRS).12 For the study, maculopathy was pri-
oritized over retinopathy when grouping the eyes and a greater differentiation
between macula grades was made. The imaged field of view was an area
centered on the fovea for comparison purposes. A custom scheme of classi-
fications for grouping the diabetic eyes in this study was defined, which
served the purpose of investigating the effect of DR and DME abnormalities
on the choroid. The grading used basic ETDRS definitions of DR and DME
abnormalities, in particular the definition for “CSME.” The diabetic eyes were
grouped for pathology within 1 disc-diameter of fovea (without pathology
[NDR], microaneurysms [M1], exudates [M2], and clinically significant mac-
ular edema [CSME]). This resulted in a total of 63 eyes from subjects with
diabetes. The distribution of diabetic retinopathy for these eyes is shown in
Table 2.
Healthy control subjects were included only if they had fewer than
three of the following risk factors for diabetes: family history of diabe-
tes, age  50 years, ethnic background, diagnosed high blood pres-
sure, heart attack, or stroke. Only nonsmokers were included. Only
one eye was included per healthy subject. Healthy subjects and eyes
were chosen to match age and axial lengths according to the mean and
SD of the diabetic groups (ANOVA; P  0.05).
Study Protocol
Monocular visual acuity was determined with ETDRS Original Series Charts
(Precision Vision, La Salle, IL). Retinal status was documented with a fundus
photograph with a 45° field centered on the macula (CR-DGi nonmydriatic
retinal camera; Canon, Lake Success, NY) after pupil dilation. Five axial eye
length (AL) measurements were averaged from each eye using optical biom-
etry (IOL Master Zeiss; Jena, Germany). All subjects had their blood pressure
(BP) measured after at least 20 minutes resting in a sitting position. All diabetic
subjects had their casual blood glucose tested. Fasting blood glucose was not
obtained, because this would have altered homeostatic mechanisms and not
allowed a representative comparison to be made between normal and dia-
betic eyes. Information about diabetes duration, weight, and height were
recorded.
OCT Imaging and Thickness Maps
High speed three-dimensional OCT imaging at 1060 nm (3D-1060nm-
OCT) was performed with  2.5 mW at the cornea, well below the
maximum power limit for 10 seconds of exposure.13,14 Three-dimen-
sional OCT volumes were acquired at 1060 nm with 15 to 20 m
transverse resolution, approximately 7 m axial resolution and 512
voxels per depth-scan (A-scan). Scans across a 36° 36° field at 47,000
A-scans per second were centered on the fovea and resulted in up to
70 frames per second. For image processing and manual measurement
of pixel distances in choroid and retina, ImageJ software was used
(developed by Wayne Rasband, National Institutes of Health, Bethesda,
MD; available at http://rsb.info.nih.gov/ij/index.html).5
The measurement of ChT and the generation of thickness maps is
described elsewhere.10 Briefly, axial RT was defined as the distance
between internal limiting membrane and the center of the peaks
originating from the RPE/Bruch’s membrane/ choriocapillaris (RBC)
complex and axial ChT as the distance between RBC complex and the
TABLE 3. Retinal Foveal and Choroidal Subfoveal Thickness
Measurements from Healthy Eyes and Eyes of Subjects with Diabetes
Range of Diabetic Maculopathies
NDR M1 M2 CSME
Healthy
Eyes
Retina, m
Mean  SD 209  15 221  32 223  42 282  72* 212  28
Range 189–238 179–292 152–304 172–374 171–277
Choroid, m
Mean  SD 214  55 208  49 205  54 211  76 327  74†
Range 114–365 122–313 122–321 117–365 207–510
CSME, clinically significant macula edema; M1; microaneurysms;
M2, exudates; NDR, without pathology; SD, standard deviation.
* Significantly different from the healthy retinal thickness
(ANOVA, P  0.001; Tukey test, P  0.01).
† Significantly different from the choroidal thickness in the dia-
betic groups (ANOVA, P  0.001; Tukey test, P  0.001).
TABLE 1. Demographic and Statistical Data of the Cohort
Age
(y)
AL
(mm)
Casual Plasma
Glucose (mmol/L)
BMI*
(kg/m2) LogMAR
SBP
(mm Hg)
DBP
(mm Hg)
Duration
(y)
NDR (n  15; males  10; BP medication  11)
Mean  SD 69  10 23.96  0.79 9  4.1 28.5  5 0.09  0.12 144  15 87  11 11  9
Range 45–81 23.09–25.59 3.8–17.3 21.4–38.9 0.1–0.7 120–174 69–101 5–40
M1 (n  19; males  15; BP medication  13)
Mean  SD 63  14 23.76  0.63 10  6 27.6  5.7 0.14  0.16 137  24 82  15 16  6
Range 42–82 22.05–24.81 3.8–22.1 15.8–35.6 0.1–0.44 99–182 58–109 6–25
M2 (n  17; males  13; BP medication  15)
Mean  SD 58  13 23.94  0.8 9.9  6.1 30.3  6.5 0.12  0.19 137  20 78  14 17  11
Range 40–79 22.45–24.95 4.2–27.8 21–40.1 0.1–0.54 99–171 58–106 6–40
CSME (n  12; males  10; BP medication  9)
Mean  SD 68  12 23.41  0.8 10.5  4.7 29.6  2.8 0.18  0.16 137  24 80  14 15  7
Range 41–80 22.4–24.51 3.7–19.4 25.7–34.8 0.06–0.5 82–171 64–106 1–25
Healthy (n  16; males  6; BP medication  5)
Mean  SD 61.31  12 23.39  0.8 24.3  3.4 0.06  0.1 131  23 79  9
Range 38–79 22.06–25.01 16.3–33.1 0.16–0.24 98–186 66–92
AL, axial eye length; BMI, body mass index; BP, blood pressure; CSME, clinically significant macula edema; DBP, diastolic blood pressure; M1,
microaneurysms within 1 disc-diameter of the fovea; M2, exudates within 1 disc-diameter; LogMAR, logarithm of the Minimum Angle of Resolution;
NDR, without pathology; SBP, systolic blood pressure; SD, standard deviation.
* Univariate ANOVA (P  0.02). Tukey test (P  0.01) for healthy and M2.
TABLE 2. Number of Eyes with Diabetic Retinopathy for Each
Maculopathy Grade
Maculopathy Grade
NDR
(n  15)
M1
(n  19)
M2
(n  17)
CSME
(n  12)
No DR 15 – – –
Background DR – 14 12 9
Pre-proliferative DR – 5 5 2
Proliferative DR – – – 1
CSME, clinically significant macula edema; DR, diabetic retinopa-
thy; M1; microaneurysms; M2, exudates; NDR, without pathology.
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choroidal–scleral interface. For the investigation of the thickness vari-
ation throughout the entire field of view, thickness maps were gener-
ated based on manual segmentation. The resulting pixel distance was
converted into optical distance using the depth sampling calibration
for the 3D-1060nm-OCT system and further to the anatomic distance.
This resulted in thickness maps for individual eyes. Individual ChT
maps were viewed at the location of recorded microaneurysms, exu-
dates, and focal edema for obvious changes in thickness.
For the statistical analysis of mean and variation, all the individual
ChT and RT maps were aligned to each other in respect to the macula
and optic nerve position with commercially available software
(MATLAB; The MathWorks, Inc., Natick, MA). ChT maps of diabetic
eyes were grouped by the category of maculopathy. Unreliable por-
tions of the images with fewer than five measurements at one location
were excluded. Mean and SD was obtained to create a compound map
of average thickness for these five groups of eyes with color-coded
thickness. The coefficient of variation was used to map the variation
within each group. Difference maps were generated to investigate the
change in ChT and RT by subtracting each diabetic category from the
healthy eyes group. An additional statistical analysis of the difference
between the healthy and each diabetic category was generated by
conducting t-tests for each individual axial thickness over the field of
view. Contour lines for P  0.05 and 0.001 were drawn on the
difference maps to show areas of statistically significant difference. For
statistical assessment of individual variation between eyes, central ChT
measurement was located beneath the foveola.
RESULTS
There was no difference between the subject groups in BP and
logMAR vision and no difference between the diabetic subject
groups for diabetes duration, logMAR, casual blood glucose
and body mass index (BMI; Table 1; ANOVA, P  0.05). Only
M2s had a significantly higher BMI than healthy subjects (post
hoc Tukey test, P  0.01).
All tomograms were of sufficient quality to allow ChT mea-
surement. Mean subfoveal ChT was thickest for the healthy
eyes (Table 3) and significantly different from all other groups
(ANOVA, P  0.001; Tukey test, P  0.001). There was no
FIGURE 1. Examples in diabetic (A-D) and healthy (E) subjects of retinal thickness maps (1), choroidal thickness maps (2), tomograms through
the center of the fovea and optic nerve (3), and enface tomograms through the Haller’s and Sattler’s layer of the choroid (4). Subjects with diabetes
had different stages of maculopathy: NDR (A), M1 (B), M2 (C), and CSME (D). All subjects had short axial eye length (A, 23.09 mm, 71 years of
age; B, 23.34 mm, 76 years of age; C, 22.78 mm, 47 years of age; D, 22.42 mm, 55 years of age; E, 22.06 mm, 66 years of age). White lines in the
horizontal represent 1 mm scale bars (for row 3, 0.5 mm vertically).
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difference between the maculopathy groups. There was no
apparent ChT decrease directly below the lesions. For a com-
parison between healthy and diabetic eyes, thickness maps
proved to be easier to interpret than single tomograms (Fig. 1).
The images from the 3D-1060nm-OCT were useful to investi-
gate overall vessel distribution in enface view through the
Haller’s and Sattler’s layer (Fig. 1, A4–E4).
Figure 2 shows averaged RT maps and difference maps with
regions of significant difference between each pathology
group and the healthy eyes. The comparison of averaged RT
maps by groups (Fig. 2) confirms that the CSME group had the
thickest macula; significantly centrally, temporally and inferi-
orly. The M2 retinal map had a small region of significant
thickening temporally. The M1 group showed that the retina
was thicker temporally but not significant in comparison with
the healthy group, with only small areas of significant thinning
above and below the optic nerve. The NDR group showed
large regions of significant thinning just outside the macular
region and in the region of the arcades.
Figure 3 shows ChT maps and difference maps with regions
of significant difference between each pathology group and
the healthy eyes. The NDR group shows an overall decrease
(P  0.001) in ChT with more significant decrease (P  0.001)
centrally, inferiorly, and temporally. The M1 group shows an
extensive significant decrease (P  0.001) in all regions of the
choroid. The M2 group also shows an overall ChT decrease
(P  0.05), with a significant decrease (P  0.001) inferiorly.
Finally, in the CSME groups, ChT is decreased overall (P 
0.05) in the far superior temporal periphery and inferiorly and
superiorly nasally.
Contour lines delineating coefficient of variation changes
show that large regions within the averaged thickness maps
have low coefficient of variation 30% (Fig. 4).
DISCUSSION
The present study is a proof of concept that shows the feasi-
bility of investigating the choroid in diabetic subjects. Healthy
FIGURE 2. Retinal thickness maps averaged for each study group (upper row) and a comparison of thickness change mapped with significant
difference contour lines (lower row). Dotted lines represent statistical significance (P  0.05). Solid lines represent statistical significance (P 
0.05).
FIGURE 3. Choroidal thickness maps averaged for each study group (upper row) and a comparison of thickness change mapped with significant
difference contour lines (lower row). Solid contour lines represent statistical significance (P  0.05); dotted lines represent P  0.001.
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subjects and patients with various stages of diabetic maculopa-
thy and retinopathy were compared by analyzing ChT subfo-
veally and peripherally using thickness maps. Subfoveally, the
choroid was approximately 35% thinner in all of the diabetic
groups compared with healthy eyes. This is above the mea-
surement variation by different operators. Choroidal measure-
ment mean interoperator difference for ChT is 2 m (limits of
agreement,47 and 52m) for a measurement in 40 eyes. This
variability is comparable to the interoperator variability of the
retina of only 16%.15 A 10% change of retinal macula volume is
clinically significant when measured with OCT16,17; a 35%
decrease is therefore highly clinically significant. It is also a
change that cannot be related to choriocapillary atrophy alone.
The choriocapillaris layer has a thickness of approximately 10
m, which is not discernable by the 3D-1060nm-OCT18 and
much thinner than the change measured in this study.
The biologic mechanisms that underlie a decrease of ChT
are uncertain. Although the choroid thinning was within most
of the field of view of the 3D-1060nm-OCT, the decrease
reached greater significance inferiorly in each diabetic group.
In a previous study of ChT, a similar trend for inferior thinning
was evident for a healthy group of subjects with mild to
moderate myopic eyes,10 which indicates that the inferior
choroid may be naturally thinner in eyes with long axial
lengths. In the retina, a lower vasodilator reserve and greater
susceptibility for ischemia is reported for the inferior retina
compared to the superior retina.19 If choroidal thinning is
indicative of a loss of choroidal capillaries, then this may
explain the increased susceptibility to retinal hypoxia and
ischemia in this region.20 In diabetes, if the oxygen supply to
the retina is further compromised by a global loss of choroidal
capillaries, then the impact on the retina would be even
greater.
The RT maps indicate a change that was not seen clinically
when using the ETDRS grading. Although the NDR group had
no signs of retinopathy or maculopathy, a significantly thinner
perimacular area than in the healthy retina is shown in the
maps (unpaired t-test, P  0.001). This may be caused by a
thinning of the neural layers or ischemia that is not visible with
Volk lens indirect ophthalmoscopy. Diabetic retinal vascula-
ture pathogenesis is explained mostly by vascular endothelium
changes and inflammation,21 but it may be that ChT change is
related to subclinical retinal changes and both occur before the
first signs of retinopathy or maculopathy are visible.
Previous studies have found retinal thinning with a mean
magnitude of 10 to 15 m in type 2 subjects with no retinop-
athy,22–24 measured at foveal or averaged over the area of the
macula. This study uses a larger field if view for RT map and
does not average thickness measurements by regions as com-
mercial OCT retinal analysis does. Conversely, NDR patients in
this study have longer diabetes duration. The choroid has been
evaluated in healthy subjects but its thickness was analyzed in
only five locations11; in this study, maps were generated to
include larger areas. A strength of this study is the similarity of
groups with respect to the characteristics age and AL, both of
which are known to affect the choroid.10,11 The eyes in this
study were grouped according to the maculopathy grade but
were carefully matched in their baseline factors AL and age. It
is possible that the thinner ChT measured in this study is
caused by diabetes and/or other factors that have a role in the
pathogenesis of diabetic retinopathy, such as hypertension,
smoking, or hyperlipidemia.25,26 Hypertension or BP medica-
tion was evenly distributed throughout the diabetic groups,
but the ratio of subjects in the healthy group with hyperten-
sion (Table 1) was considerably lower.
In conclusion, the retinal maps showed a variation that
matched the implicit pathogenesis of diabetic eye disease.
Averaged ChT maps showed an overall decrease for all grades
of diabetes in comparison with healthy eyes. The thickness
decrease in subfoveal and inferior regions of the choroid may
be related to early, preclinical changes in diabetes. Additional
investigation into the cause of the choroidal thinning is war-
ranted.
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